海王生物(000078) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥9,201,630,764.82, a decrease of 9.20% compared to ¥10,133,836,664.76 in the same period last year[4] - Net profit attributable to shareholders was ¥70,927,976.38, down 22.48% from ¥91,496,225.03 year-on-year[4] - Basic and diluted earnings per share were both ¥0.0269, representing a decline of 19.22% from ¥0.0333 in the same period last year[4] - The total operating revenue for the first quarter was ¥9,201,630,764.82, a decrease of 9.2% compared to ¥10,133,836,664.76 in the previous year[26] - The total operating costs for the first quarter were ¥9,074,076,507.26, down from ¥9,934,059,742.69, reflecting a reduction of 8.7%[26] - The net profit for the current period is CNY 100,718,458.35, a decrease of 29.5% compared to CNY 143,104,341.40 in the previous period[29] - The total profit for the current period is CNY 135,094,285.04, down from CNY 208,608,437.67, reflecting a decline of 35.1%[29] - The total comprehensive income attributable to the parent company's owners is CNY 70,927,976.38, compared to CNY 90,554,667.53, a decrease of 21.7%[33] - Basic and diluted earnings per share decreased to CNY 0.0269 from CNY 0.0333, a decline of 19.3%[33] Cash Flow - The net cash flow from operating activities decreased by 56.92%, amounting to ¥167,896,816.35 compared to ¥389,753,412.22 in the previous year[4] - The cash flow from operating activities for the current period is CNY 167,896,816.35, down 57.0% from CNY 389,753,412.22 in the previous period[34] - The cash inflow from operating activities totaled CNY 9,490,023,016.36, down 6.4% from CNY 10,143,908,188.10[34] - The cash outflow from operating activities was CNY 9,322,126,200.01, a decrease of 4.4% compared to CNY 9,754,154,775.88[34] - Cash inflow from financing activities totaled approximately $4.02 billion, a decrease of 32.1% from $5.92 billion in the previous period[40] - Cash outflow from financing activities amounted to about $4.62 billion, down 19.5% from $5.74 billion year-over-year[40] - Net cash flow from financing activities was negative at approximately -$599.69 million, contrasting with a positive $182.50 million in the prior period[40] - The ending balance of cash and cash equivalents was approximately $533.01 million, a significant decrease from $1.84 billion at the end of the previous period[40] - The net increase in cash and cash equivalents was negative at -$446.82 million, compared to a positive increase of $348.26 million previously[40] Assets and Liabilities - Total assets at the end of the reporting period were ¥36,942,029,945.71, a decrease of 1.76% from ¥37,603,849,419.61 at the end of the previous year[4] - The total assets decreased to ¥36,942,029,945.71 from ¥37,603,849,419.61, representing a decline of 1.8%[21] - The total liabilities decreased to ¥29,549,172,806.75 from ¥30,295,590,943.09, showing a reduction of 2.5%[25] - The company's inventory decreased to ¥3,521,680,864.95 from ¥3,792,908,469.56, a decline of 7.1%[18] - The cash and cash equivalents at the end of the period amounted to ¥3,742,341,870.87, down from ¥4,127,017,083.57 at the beginning of the year, indicating a decrease of 9.4%[18] - The company's total equity attributable to shareholders was ¥5,893,059,318.74, an increase of 1.22% from ¥5,822,126,598.89 at the end of the previous year[4] - The company's retained earnings increased to ¥1,056,620,320.90 from ¥985,687,601.05, marking a growth of 7.2%[25] - The long-term equity investments increased slightly to ¥390,622,871.68 from ¥385,006,728.76, reflecting a growth of 1.6%[21] Other Income and Expenses - The company's other income increased by 143.02% year-on-year, primarily due to increased pandemic-related subsidies[8] - Cash received from investment increased by 310.22% year-on-year, attributed to a rise in redeemed structured deposits[8] - Cash flow from financing activities decreased by 428.60% year-on-year, mainly due to loan repayments[8] - The company reported a decrease in investment income cash flow by 85.25% year-on-year, due to reduced dividends from joint ventures[8] - Sales expenses decreased to CNY 381,096,502.80 from CNY 409,275,813.02, a reduction of 6.5%[29] - Research and development expenses decreased to CNY 11,543,209.87 from CNY 12,835,341.47, a decline of 10.1%[29] Development and Restructuring - The company received approval for the clinical trial of "ABRJ oral microemulsion" from the National Medical Products Administration in April 2021, indicating ongoing product development efforts[14] - The company is in the planning stage for significant asset restructuring and mixed ownership reform, which carries substantial uncertainty[14] Audit Status - The company’s first quarter report was not audited[41]